| Titre : | Cost effectiveness of statins in coronary heart disease. (2005) |
| Auteurs : | Oscar-H FRANCO ; BONNEUX (Luc) : BEL. Belgian Health Care Knowledge Centre (Kce). Brussels. ; Caspar-Wn LOOMAN ; PEETERS (Anna) : AUS. Department of Epidemiology and Preventive Medicine. Monash University Central and Eastern Clinical School. Melbourne. |
| Type de document : | Article |
| Dans : | Journal of epidemiology and community health (vol. 59, n° 11, 2005) |
| Pagination : | 927-933 |
| Langues: | Anglais |
| Mots-clés : | Analyse coût efficacité ; Economie santé ; Cardiopathie coronaire ; Enzyme ; Homme ; Thérapeutique médicamenteuse ; Chimiothérapie ; Thérapeutique ; Appareil circulatoire [pathologie] |
| Résumé : | [BDSP. Notice produite par INIST-CNRS sVfR0xBY. Diffusion soumise à autorisation]. Introduction : Statin therapy reduces the rate of coronary heart disease, but high costs in combination with a large population eligible for treatment ask for priority setting. Although trials agree on the size of the benefit, economic analyses of statins report contradictory results. This article reviewed cost effectiveness analyses of statins and sought to synthesise cost effectiveness ratios for categories of risk of coronary heart disease and age. Methods : The review searched for studies comparing statins with no treatment for the prevention of either cardiovascular or coronary heart disease in men and presenting cost per years of life saved as outcome. Estimates were extracted, standardised for calendar year and currency, and stratified by categories of risk, age, and funding source Results : 24 studies were included (from 50 retrieved), yielding 216 cost effectiveness ratios. Estimated ratios increase with decreasing risk. After stratification by risk, heterogeneity of ratios is large varying from savings to $59 000 per life year saved in the highest risk category and from $6500 to $490 000 in the lowest category. The pooled estimates show values of $21571 per life year saved for a 10 year coronary heart disease risk of 20% and $16862 per life year saved for 10 year risk of 30%. Conclusion : Statin therapy is cost effective for high levels of risk, but inconsistencies exist at lower levels. Although the cost effectiveness of statins depends mainly on absolute risk, important heterogeneity remains after adjusting for absolute risk. Economic analyses need to increase their transparency to reduce their vulnerability to bias and increase their reproducibility. |
Service Documentation EHESP
Me connecter
PORTAIL DOCUMENTAIRE
École des hautes études en santé publique
Catalogue
Multi-bases
Accueil
Sélection de la langue
Adresse
Service Documentation EHESPBibliothèque Rennes Avenue du Professeur Léon Bernard – CS 74312 – 35043 Rennes Cedex Bibliothèque MSSH Paris 20 avenue George Sand - 93210 La Plaine Saint-Denis
France
Bibliothèque Rennes : 02 99 02 29 50 Bibliothèque MSSH Paris : 02 99 02 24 50
contact